Overview

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Status:
RECRUITING

Trial end date:
2030-03-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Phase:

PHASE1

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Gemcitabine
glofitamab
obinutuzumab
Oxaliplatin
tocilizumab